173 related articles for article (PubMed ID: 38019080)
1. Markers of refractory primary immune thrombocytopenia.
Moulis G; Garabet L
Br J Haematol; 2023 Oct; 203(1):112-118. PubMed ID: 38019080
[TBL] [Abstract][Full Text] [Related]
2. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
[TBL] [Abstract][Full Text] [Related]
5. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada.
Britto J; Holbrook A; Sun H; Cserti-Gazdewich C; Prokopchuk-Gauk O; Hsia C; Khamisa K; Yenson PR; Sholzberg M; Olney HJ; Shivakumar S; Jones D; Merkeley H; Costello J; Jamula E; Arnold DM
Clin Invest Med; 2024 Mar; 47(1):13-22. PubMed ID: 38546381
[TBL] [Abstract][Full Text] [Related]
8. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment.
Ghanima W; Gernsheimer T; Kuter DJ
Blood; 2021 May; 137(20):2736-2744. PubMed ID: 33827138
[TBL] [Abstract][Full Text] [Related]
9. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
10. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
Vibor M; Rogulj IM; Ostojic SK
Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
Ayad N; Grace RF; Al-Samkari H
Pediatr Blood Cancer; 2022 Mar; 69(3):e29447. PubMed ID: 34962697
[TBL] [Abstract][Full Text] [Related]
12. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment.
Mageau A; Terriou L; Ebbo M; Souchaud-Debouverie O; Orvain C; Graveleau J; Lega JC; Ruivard M; Viallard JF; Cheze S; Dossier A; Bonnotte B; Perlat A; Gobert D; Costedoat-Chalumeau N; Jeandel PY; Dernoncourt A; Michel M; Godeau B; Comont T
Am J Hematol; 2022 Jan; 97(1):10-17. PubMed ID: 34661954
[TBL] [Abstract][Full Text] [Related]
13. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
Červinek L; Mayer J; Doubek M
Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
[TBL] [Abstract][Full Text] [Related]
17. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
[TBL] [Abstract][Full Text] [Related]
18. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia.
Mahévas M; Gerfaud-Valentin M; Moulis G; Terriou L; Audia S; Guenin S; Le Guenno G; Salles G; Lambotte O; Limal N; Viallard JF; Cheze S; Tomowiak C; Royer B; Neel A; Debouverie O; Hot A; Durieu I; Perlat A; Cliquennois M; Deteix C; Michel M; Godeau B
Blood; 2016 Sep; 128(12):1625-30. PubMed ID: 27354722
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia.
Pizzi M; Vianello F; Binotto G; Vianelli N; Carli G; Auteri G; Nichele I; Sbaraglia M; Zoletto S; Scarmozzino F; Bresciani R; d'Amore F; Friziero A; Guzzardo V; Bertozzi I; Famengo B; d'Amore ESG; Sabattini E; Dei Tos AP
Br J Haematol; 2022 Sep; 198(5):916-922. PubMed ID: 35701886
[TBL] [Abstract][Full Text] [Related]
20. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
Iino M; Sakamoto Y; Sato T
Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
